Compare Recursion Pharmaceuticals Inc (RXRX) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Ryanair Holdings plc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.09 (market cap $2.14B), while Ryanair Holdings plc trades at $52.92 (market cap $27.11B). The key difference: Ryanair Holdings plc is far larger — about 12.7× Recursion Pharmaceuticals Inc's market cap, and Ryanair Holdings plc pays a 1.66% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Ryanair Holdings plc for 72 Days on average.
| RXRX | RYAAY | |
|---|---|---|
Market Cap | $2.14B | $27.11B |
Volume | 30,789,535 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $6.79 | $73.82 |
52-Week Low | $2.84 | $51.95 |
Typical Hold Time | 22 Days | 72 Days |
Enterprise Value | $1.66B | $24.18B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
RYAAY trades at $53.1, down 5.18% on the day, reflecting a bearish technical signal amid mixed earnings performance. The company maintains strong profitability with a 12.13% net income margin and 22.41% ROE, while valuation metrics like a P/E of 13.43 appear attractive. Recent news highlights CEO commentary on Boeing MAX 10 certification delays and concerns over rising fuel costs impacting future airfares.
The stock presents a value opportunity given its low valuation multiples and robust cash flow generation, but faces near-term headwinds from volatile fuel prices and a lowered FY27 traffic outlook. Analyst consensus remains moderately bullish, though technical indicators suggest caution. Key risks include oil price sensitivity and competitive pressures in the European airline sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
